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Abstract
Dietary polyunsaturated fatty acids (PUFA), especially eicosapentaenoic acid (EPA), improve lipid metabolism and
contribute to the prevention of vascular diseases such as atherosclerosis. However, EPA in the diet is easily oxidized
at room temperature and several types of oxidized EPA (OEPA) derivatives are generated. To compare the
efficiencies of OEPAs on lipid metabolism with EPA, human hepatocellular liver carcinoma cell line (HepG2) was
treated with EPA or OEPAs and their effects on lipid metabolism related genes were studied. OEPAs more potently
suppressed the expression of sterol-responsive element-binding protein (SREBP)-1c, a major transcription factor that
activates the expression of lipogenic genes, and its downstream target genes than did EPA under conditions of
lipid synthesis enhanced by T0901317, a synthetic liver X receptor (LXR) agonist. Furthermore, PGC-1β, a coactivator
of both LXRα and SREBP-1, was markedly down-regulated by OEPAs compared with EPA. The treatment of OEPAs
also significantly down-regulated the expression of glycerol-3-phosphate acyltransferase (GPA), the initiating
enzyme in triacylglycerol (TG) synthesis, more than EPA. Therefore, the advantageous effects of OEPAs on
cardiovascular diseases might be due to their SREBP-1c, PGC-1β and GPA mediated ameliorating effects.
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Introduction
Triacylglycerol (TG), in either the serum or the liver, is a
major risk factor for cardiovascular disease (CVD) [1-3].
With respect to the importance of hepatic TG levels,
nonalcoholic fatty liver disease (NAFLD) is highly asso-
ciated with CVD [4-7]. Several prospective epidemio-
logical studies recently demonstrated that both an
increased liver enzyme concentration in the serum [8,9]
and hepatic steatosis determined by ultrasound [6,7] are
able to predict the development of CVD independent of
alcohol consumption or traditional CVD risk markers,
such as serum LDL cholesterol concentrations. In addition,
Rijzewijk et al. demonstrated that type 2 diabetes mellitus
patients with high liver TG content showed a decreased
myocardial perfusion compared with similar diabetes
patients with low liver TG content [3]. Therefore, the
dysfunction of hepatic lipid metabolism has been of con-
cern as a therapeutic target of CVD.
Omega-3 polyunsaturated fatty acids (PUFAs), espe-
cially eicosapentaenoic acid (EPA), have been developed
commercially as dietary supplements due to their vari-
ous health benefits, particularly their ameliorating effect
on CVD [10,11]. EPA has TG-reducing effects in
normolipidemic [12] and in hyperlipidemic subjects [13].
It has been proposed that EPA decreases TG through
the regulation of peroxisome proliferator-activated re-
ceptor α (PPARα) and sterol regulatory element-binding
protein (SREBP)-1, which govern hepatic fatty acid (FA)
catabolism and synthesis, respectively [14]. It has been
well established that SREBP-1c is the major isoform
expressed in the liver and in tissues involved in energy
homeostasis [15]. Hence, the dysregulation of SREBP-1c
has been implicated in the pathogenesis of hepatic
steatosis and dyslipidemia, which are closely related
to CVD including atherosclerosis [16,17]. SREBP-1c
* Correspondence: sugawara@kais.kyoto-u.ac.jp
Division of Applied Biosciences, Graduate School of Agriculture,
Kyoto University, Kyoto 606-8502, Japan
© 2013 Nanthirudjanar et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Nanthirudjanar et al. Lipids in Health and Disease 2013, 12:73
http://www.lipidworld.com/content/12/1/73
transcription is enhanced by insulin and by agonists
of liver X receptor α (LXRα) [18].
Glycerol-3-phosphate acyltransferase (GPA) is supposed
to be a rate-limiting step in TG and phospholipid biosyn-
thesis. It catalyzed the first step in glycerophospholipid syn-
thesis by acting as the esterification of glycerol-2-phosphate
in the sn-1 position with a fatty acyl-CoA to form
1-acylglycerol-3-phosphate (lysophosphatidic acid). Ly-
sophosphatidic acid is further esterified by 1-acyl-
glycerol-3-phosphate acyltransferase (AGPAT) to form
1,2-diacylglycerol-3-phosphate (phosphatidic acid), which
is the precursor of TG and phospholipids [19]. The study
by Lewin et al. showed that mice deficient in mitochon-
drial GPA have diminished myocardial TG accumulation
during lipogenic diet [20]. Therefore, a decrease of the
expression of GPA in the liver might prevent hepatic
steatosis and dyslipidemia.
A recent study demonstrated that peroxisome
proliferator-activated receptor γ coactivator 1β (PGC-1β)
is a potent activator of mitochondrial gene expression, in-
cluding genes regulating the β-oxidation of fatty acids, but
has relatively little ability to stimulate the program of glu-
coneogenesis [21]. Furthermore, PGC-1β has also been
reported to co-activate the LXR and SREBP families and
to elevate circulating TG and cholesterol in VLDL parti-
cles [22]. As mentioned above, PGC-1β might be a cofac-
tor connecting the regulation of fatty acids with the
ameliorating effect on TG accumulation in the liver.
Oxidation products of omega-3 fatty acids, especially
EPA and DHA, play crucial roles in the palliative effects via
many mechanisms especially those that are cardiovascular-
related. A study by Majkova et al. showed that components
of oxidized DHA can alleviate the endothelial dysfunction
caused by coplanar PCB77 [23]. Furthermore, oxidized EPA
(OEPA) has been shown to inhibit leukocyte-endothelial in-
teractions by potently activating PPARα in endothelial cells,
and to do so to a much greater extent than native EPA.
Although native EPA activates PPARα about half as well
as OEPA, unlike EPA, OEPA has effects on leukocyte-
endothelial interactions in vitro and in vivo [24]. 5-HEPE, a
metabolite produced from EPA in human neutrophils and
eosinophils, has been shown to be a potent agonist for G
protein-coupled receptor (GPR) 119, which results in a re-
duction in food intake and in body weight gain in rats [25],
and to enhance glucose-dependent insulin secretion [26].
However, the effects of OEPA on many processes are
still obscure. Therefore, we aimed to elucidate the mech-
anism of 4–24 h OEPAs which are composed of various
species of oxidation products on lipid metabolism, par-
ticularly via the LXRα and SREBP-1c pathway, which
plays an important role in lipid metabolism in liver cells.
Surprisingly, we found that OEPA significantly down-
regulates the expression of lipogenic genes, which results
in the suppression of hepatocellular TG more than EPA.
Results
Changes in derivatives of EPA oxidation products after
auto-oxidation
First, OEPAs were prepared from EPA (10 mg) by auto-
oxidation. [M-H]- at the mass to charge ratio (m/z)
301.2 presented as the molecular ion of EPA and m/z
317.2-397.2 were presumably derived from EPA oxida-
tion products. The intensity of the molecular ion of EPA
at m/z 301.2 decreased continuously after auto-oxidation
and remained around 50% of the pre-incubation level of
EPA at 24 h under these experimental conditions. After
oxidation for 4 h, several new ions that were oxidative
products of EPA appeared. The molecular ion [M-H]- of
hydroxy-EPA (HEPE) at m/z 317.2 reached a peak at 4 h
incubation and then gradually decreased. HEPE was the
major EPA oxidation product at 4 and 8 h. The ion at m/z
333.2, known as hydroperoxy-EPA, appeared after 4 h of
auto-oxidation and increased gradually from 8 to 24 h. On
the other hand, the ion at m/z 349.2 was detected at 8 h
and after that it reduced gradually. The ions at m/z 365.2
and 397.2 were found at 4 and 8 h, respectively, and then
they tended to increase gradually (Figure 1).
Effects of each fatty acid on HepG2 cell viability
To ascertain the effects of each compound on cell viabil-
ity, various concentrations of fatty acids and T0901317
were added to HepG2 liver cells in culture. Figure 2
shows the results of the viability assay after 24 h of treat-
ment. The cytotoxic effect of EPA weakened depending
on the oxidation time. EPA, 4 h OEPA, 8 h OEPA and
16 h OEPA at 30 and 60 μM significantly reduced cell
viability to around 24%, 34%, 34% and 66% of vehicle-
treated control cells, respectively. The 24 h OEPA at
30 μM, but not at 60 μM, had no cytotoxic effect on























































Figure 1 Ion intensities derived from EPA and EPA oxidation
products analyzed by LC/MS. m/z 301.2 was derived from EPA
and m/z 317.2-397.2 were presumably derived from hydroxy- and
hydroperoxy-EPAs. Each oxidized EPA was prepared from EPA
(10 mg) incubated in 40°C water bath for 4, 8, 16 or 24 h.
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Notwithstanding, when HepG2 cells were co-incubated
with 10 μM vitamin E, the cytotoxicity of EPA and OEPA
was eliminated, which corresponded with the study of
Caputo et al. [27].
OEPA suppresses TG synthesis in HepG2 cells
We examined the effects of EPA and each OEPA on TG
synthesis in T0901317-induced HepG2 cells. While the
cells were being treated with each compound, vitamin E
was simultaneously added in FBS-free medium containing
0.1% BSA since EPA has very severe cytotoxic effects, as
shown in Figure 2. T0901317 significantly augmented the
cellular level of TG (about 3200 μg/mg protein) after 48 h
of incubation. Consistent with a previous study [25], EPA
significantly reduced TG synthesis of T0901317-treated
HepG2 cells to 2400 μg/mg protein. Surprisingly, treat-
ment with OEPA for 4, 8 and 16 h significantly inhibited
the cellular TG content of HepG2 cells more than did
EPA (Figure 3). Moreover, the 24 h OEPA, which has
around 50% the ion intensity at m/z 301.2 to intact EPA
(Figure 1), showed almost the same level of TG suppres-
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Figure 2 Effects of EPA and OEPA on cell viability as determined by the water soluble tetrazolium (WST)-1 assay. Each fatty acid (30 or
60 μM) was added to HepG2 cells with T0901317 (10 nM) and/or vitamin E (10 μM) in serum-free medium containing 0.1% BSA. The final ethanol
concentration was 0.3%. After 24 h incubation, the WST-1 solution was added to the cells. The absorbance at 450 nm corresponds to cell viability.
Expression levels are presented as relative percentage to vehicle control (ethanol). Data are reported as means ± SD (n = 4/group). * A significant
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Figure 3 Effects of EPA and OEPA on TG synthesis in HepG2 cells. Each fatty acid (60 μM) was added to HepG2 cells with T0901317 (10 nM)
and vitamin E (10 μM) as noted in serum-free medium containing 0.1% BSA for 48 h. The final ethanol concentration was 0.3%. The increased TG
level per mg protein (TG level after 48 h of incubation minus the level of reference cells) is shown. Data are reported as means ± SD (n = 3-4/
group). Values with different letters are significantly different (p < 0.05).
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that HEPEs might play a crucial role in the effect of EPA
on the inhibition of cellular TG synthesis in HepG2 liver
cells.
OEPA decreases SREBP-1c mRNA expression and
maturation more effectively than EPA
To determine whether the hypolipogenic effect of OEPA
on HepG2 cells is due to SREBP-1c, the mRNA expres-
sion levels of SREBP-1c and SREBP-1 protein levels were
determined. The expression of SREBP-1c mRNA in cells
treated with 10 nM T0901317 was 9.4-fold higher than
in vehicle-treated control cells (Figure 4A). Treatment
with EPA and 4–24 h OEPA significantly down-regulated
SREBP-1c mRNA expression stimulated by T0901317. In
agreement with the result of TG accumulation, the sup-
pressive effect of OEPA at 4 and 8 h was statistically stron-
ger than EPA. The 4 h OEPA treated cells showed the
least SREBP-1c mRNA expression as also noted in the ef-
fect on TG synthesis in hepatocytes. Furthermore, the
24 h OEPA reduced SREBP-1c expression to the same
level as treatment with EPA (similar to Figure 3).
To investigate the effect of these fatty acids on SREBP-
1 protein levels, the full-length precursor form in cell
membranes (125 kDa) and the cleaved mature form
(68 kDa) in nuclear extracts were estimated by immuno-
blotting. Because the antibody used cannot distinguish
between the SREBP-1c and -1a isoforms, we use the
general term SREBP-1 to refer to the results. Represen-
tative blots are shown in Figure 4B and C. T0901317 in-
creased the levels of both the precursor and the mature
forms of SREBP-1. The 4–16 h OEPA as well as EPA sig-
nificantly decreased the T0901317 induction of both the
precursor and mature forms of SREBP-1. On the other
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Figure 4 Effects of EPA and OEPA on the expression of sterol-
regulatory element binding protein-1 (SREBP-1). A: Effect on
SREBP-1c mRNA expression. Each fatty acid (60 μM) was added to
HepG2 cells with T0901317 (10 nM) and vitamin E (10 μM) as noted
in serum-free medium containing 0.1% BSA. The final ethanol
concentration was 0.3%. After 24 h incubation, SREBP-1c mRNA
levels were quantified by real-time quantitative PCR. Each value of
SREBP-1c mRNA was adjusted by that of 18 s rRNA (internal control).
Expression levels are presented as -fold induction relative to the
vehicle control (vitamin E and ethanol). Data are reported as means ±
SD (n = 3/group). Values with different letters are significantly
different (p < 0.05). B,C: Effects on precursor and mature SREBP-1
protein expression. Each fatty acid was added to HepG2 cells with
T0901317 (10 nM) and vitamin E (10 μM) as noted in serum-free
medium containing 0.1% BSA. The final ethanol concentration was
0.3%. Representative Western blots are shown. The data represent
the mean -fold change of the precursor and the mature forms of
SREBP-1 from the vehicle control (ethanol). Data are reported as
means ± SD (n = 3-4/group). Values with different letters are
significantly different (p < 0.05).
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mature SREBP-1. Corresponding to SREBP-1c mRNA
expression, the precursor form of SREBP-1 was down-
regulated by treatment with the 4 and 8 h OEPA more
significantly than EPA. Interestingly, the mature form of
SREBP-1 was also inhibited by the 4 h OEPA more sig-
nificantly than EPA and the vehicle control.
Regulation of mRNA levels of lipogenic genes by OEPA
To further elucidate whether the more efficient effect
on the reduction of hepatic TG synthesis by OEPA
compared to EPA is due simply to the suppression of
SREBP-1c or also to other pathways that might be in-
volved, SREBP-1c target genes and other lipid metab-
olism related genes were examined. Treatment with
EPA or 4 h OEPA significantly decreased the expres-
sion of Acetyl CoA carboxylase (ACC), Fatty acid syn-
thase (FAS) and Stearoyl-coenzyme A desaturase-1
(SCD1) mRNAs (Figure 5A,B,C). Corresponding to the
aforementioned results, treatment with 4 h OEPA sig-
nificantly decreased ACC and FAS expression more
than the vehicle control while treatment with EPA re-
duced the expression of these genes to the same level
as the vehicle control (Figure 5A,B). Moreover, 4 h
OEPA treatment significantly down-regulated the
T0901317-induced expression of SCD1 more than did
EPA (Figure 5C). GPA, an enzyme located in the endo-
plasmic reticulum and the mitochondrial membrane
that is required for TG synthesis in the glycerol phos-
phate pathway, which is regulated by SREBP-1c, was
significantly weakened by 4 h OEPA compared to
LXRα agonist-induced cells, while EPA did not affect
the increase of GPA induced by T0901317 (Figure 5D).
In agreement with the decreased expression of lipo-
genic target genes of SREBP-1c, mRNA expression
levels of ATP-binding cassette transporter A1
(ABCA1), the other target gene of SREBP-1c that is
related to cholesterol transport, was significantly de-
creased by 4 h OEPA, but was not significantly
changed by EPA (Figure 5E). We unexpectedly found
that after the 4 h OEPA treatment, the expression of
PGC-1β, the co-activator of LXRα and the SREBP
families, was significantly down-regulated in the
T0901317-induced group. In contrast, EPA did not
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Figure 5 Effects of EPA and OEPA on the expression of acetyl-CoA carboxylase-1 (ACC; A), fatty acid synthase (FAS; B), stearoyl-
coenzyme A desaturase-1 (SCD-1; C), glycerol-3-phosphate acyltransferase (GPA; D), ATP-binding cassette sub-family A member 1
(ABCA1; E) and peroxisome proliferator-activated receptor γ co-activator 1β (PGC-1β; F) mRNAs. Each fatty acid (60 μM) was added to
HepG2 cells with T0901317 (10 nM) and vitamin E (10 μM) as noted in serum-free medium containing 0.1% BSA. The final ethanol concentration
was 0.3%. After 24 h incubation, ACC, FAS, SCD-1, GPA, ABCA1 and PGC-1β mRNA levels were quantified by real-time quantitative PCR. Values of
ACC, FAS, SCD-1, GPA, ABCA1 and PGC-1β mRNAs was adjusted by that of 18 s rRNA (internal control). Expression levels are presented as -fold
induction relative to the vehicle control (vitamin E and ethanol). Data are reported as means ± SD (n = 3/group). Values with different letters are
significantly different (p < 0.05).
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Regulation of lipogenic gene mRNA levels by 5-, 11- and
18-HEPEs
From the results mentioned above, the 4 and 8 h OEPAs,
which contain high portions of HEPEs (m/z 317.2),
showed dominant suppressive effects on the lipogenesis
pathway in HepG2 hepatic cells induced by the synthetic
LXRα agonist among EPA and other OEPAs which con-
tain lower portions of HEPEs. For this reason, we then
used the standards of HEPEs, including 5-, 11- and 18-
HEPEs, to identify the kinds of HEPEs that occurred in
the auto-oxidized process by LC-MS. The results showed
that 5-, 11- and 18-HEPEs might be members of HEPEs in
OEPA due to their correlate retention time between peaks
of the standards and HEPEs derivative in 4 h OEPA.
We then used these standard HEPEs to treat HepG2
cells to confirm whether those HEPEs are involved in
the TG reduction of OEPAs. At both 30 and 60 μM con-
centrations, all fatty acids significantly decreased the
augmentation of SREBP-1c expression caused by the
LXRα agonist. It was noteworthy that at a 60 μM con-
centration, 5-HEPE and 18-HEPE significantly reduced
SREBP-1c expression more than did EPA (Figure 6A).
The expression of SREBP-1c target genes also had a ten-
dency for the same responses. All fatty acids significantly
down-regulated the T0901317-induced increase of ACC.
At 30 μM, expression of ACC in the 18-HEPE treated
group was significantly lower than in the EPA-treated
group. In addition, 60 μM 5-HEPE or 18-HEPE signifi-
cantly reduced the expression of ACC more than did
EPA (Figure 6B). Expression of SCD1 at both 30 μM and
60 μM 18-HEPE was significantly lower than was elicited
by EPA at similar concentrations (Figure 6D). On the
other hand, all fatty acids significantly down-regulated
the T0901317-induced expression of FAS, but there was
no significant different between any of the fatty acids at
the same concentrations (Figure 6C). Among all experi-
mental groups, only treatment with 60 μM 18-HEPE
significantly decreased GPA expression compared with
T0901317-stimulated cells. Interestingly, cells which
were treated with all types of HEPEs in this experiment
had significantly reduced expression of GPA more than
the EPA-treated cells (Figure 6E). Similar to the 4 h
OEPA treatment, 18-HEPE at a high dose can signifi-
cantly decrease the expression of PGC-1β (Figure 6F).
Discussion
Previous studies showed that oxidation products of EPA
and DHA alleviate some pathways related to CVD
[23-26]. In this study, we emphasized the hypolipidemic
effect of OEPA on hepatic cells. The hypolipidemic ef-
fect of PUFAs, including EPA, is attributable both to a
decrease in lipogenesis and an increase in fatty acid ca-
tabolism through the regulation of SREBP-1 and PPARα,
respectively [14]. Nevertheless, it is well known that
PPARα weakly expresses and has very low function in
HepG2 cells, because the cells are originated from hepa-
toma and some kinds of genes, such as PPARα, is mutated
[28]. Thus, we focused on the regulation of lipogenesis via
SREBP-1 by OEPA in this study.
First of all, we noticed that 4–16 h OEPA significantly
decreased the T0901317-induced accumulation of TG in
liver cells more than did intact EPA. In this experiment,
4 h OEPA was the most effective agent which was able
to suppress TG accumulation. In accordance with that
result, the T0901317 induced expression of SREBP-1c, a
major transcription factor that activates the expression
of lipogenic genes, was significantly down-regulated by
4–8 h OEPA more than EPA. Not only the expression
level of SREBP-1c mRNA, but the protein level of
SREBP-1c was also significantly inhibited by OEPA more
than by EPA. It has been well established that PUFAs
suppress SREBP-1c pathway via competing with LXRα
ligands in the activation of the ligand binding domain
[29-31]. Our previous study showed that trans isomers
of EPA (TEPA), similar to EPA, reduces the expression
of SREBP-1c through LXRα pathway [29]. Thus, OEPA
might decrease the expression of SREBP-1c by compet-
ing with LXRα ligands more effectively than EPA.
SREBP-1c target genes were also evaluated after simul-
taneously treating HepG2 cells with T0901317, and EPA
or 4 h OEPA. As expected, ACC, FAS and SCD-1
mRNA expression in the 4 h OEPA-, but not EPA-,
treated group was significantly lower than the vehicle
control group. Furthermore, 4 h OEPA significantly de-
creased SCD-1 more than did EPA. Surprisingly, 4 h
OEPA significantly diminished the T0901317-induced
expression of GPA, but EPA did not. In agreement with
our previous finding, the TEPA significantly impaired
GPA mRNA expression as well [29]. GPA is the rate lim-
iting enzyme required for the de novo synthesis of TG
and phospholipids [32,33]. Hence, a decrease of GPA ex-
pression in the liver of OEPA might implicate in its
preferable hypolipidemic effect. Deletion of the gene en-
coding SREBP-1c has been shown to result in the failure
of T0901317-induced GPA mRNA expression in animal
studies [34,35]. However, our previous and present
studies illustrate that EPA, which can significantly
down-regulate T0901317-induced SREBP-1c expression,
cannot abate GPA expression [29]. Therefore, it can be
hypothesized that not only SREBP-1c, but also other fac-
tors, might regulate GPA expression. Ericsson et al. [36]
demonstrated that GPA promoter-luciferase reporter
genes are stimulated by the co-expression of SREBP-1a.
Importantly, that increase was attenuated when either a
dominant negative form of nuclear factor-Y (NF-Y) was
cotransfected into the cells or when the GPA promoter
contained mutations in the putative binding sites for
SREBP-1a or NF-Y. Taken together, modification of the
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molecular structure of EPA, such as OEPA and TEPA,
might be necessary for it to be involved in GPA down-
regulation via SREBP-1a or NF-Y.
These results could be also attributable in part to the
suppression of PGC-1β expression by 4 h OEPA (Figure 5F),
because PGC-1β plays dual roles in modulating hepatic
fatty acid metabolism and regulating either fatty acid
oxidation or de novo fatty acid synthesis by co-activating
SREBP-1 and LXRα [22,37]. Our data support the concept
that PGC-1β is important for the full induction of lipogenic
genes regulated by SREBP-1 and LXRα, and thus, PGC-1β
provides a therapeutic target for the metabolic syndrome. It
was shown that PGC-1β is a key regulator of hepatic lipo-
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Figure 6 Effects of EPA, 5-HEPE, 11-HEPE and 18-HEPE on the expression of sterol-regulatory element binding protein-1c (SREBP-1c;
A), acetyl-CoA carboxylase-1 (ACC; B), fatty acid synthase (FAS; C), stearoyl-coenzyme A desaturase-1 (SCD-1; D), glycerol-3-phosphate
acyltransferase (GPA; E) and peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β; F) mRNAs. Each fatty acid (60 μM) was
added to HepG2 cells with T0901317 (10 nM) and vitamin E (10 μM) as noted in serum-free medium containing 0.1% BSA. The final ethanol
concentration was 0.3%. After 24 h incubation, SREBP-1c, ACC, FAS, SCD-1, GPA and PGC-1β mRNA levels were quantified by real-time
quantitative PCR. The value of each mRNA was adjusted by that of 18 s rRNA (internal control). Expression levels are presented as -fold induction
relative to the vehicle control (vitamin E and ethanol). Data are reported as means ± SD (n = 3/group). * A significant difference from the
T0901317 vehicle control group (p < 0.05).
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intake of saturated fats [22]. In contrast, it has minimal
effect on the expression of gluconeogenic genes [21].
The expression of PGC-1β in the liver is strongly in-
duced by dietary fats, likely through direct regulation by
fatty acids in heptocytes. Hence, the effective inhibition
of the cellular TG synthesis by OEPA might be caused
by the reduction of PGC-1β expression. Notwithstand-
ing, the mechanism by which OEPA decreases PGC-1β
mRNA is unclear, but the reduction of mRNA expres-
sion of PGC-1β by OEPA is consistent with the results
of our previous report concerning about TEPA [29].
Thus, OEPA and TEPA might suppress the expression
of PGC-1β by the same mechanism.
All the aforementioned results confirm that treatment
with 4 h OEPA is the most effective in suppressing the
hepatic lipogenesis pathway among OEPAs incubated
for different oxidation times in this experiment. Inter-
estingly, these inhibition trends are associated with the
change in intensity of the ion at m/z 317.2, which
appeared as HEPEs in OEPA. Therefore, we assume that
HEPEs, but not every oxidation product, might be the
most effective oxidation product which plays a crucial
role in lipid accumulation in the liver through SREBP-
1c pathway inhibition.
It was presumed that HEPEs in the 4 h OEPA includes
5-, 11- and 18-HEPEs by LC/MS analysis compared with
HEPEs standards. Similar to the effect of 4 h OEPA, 5-
and 18-HEPEs also significantly suppressed the T0901317-
induced expression of SREBP-1c, ACC and SCD-1 more
than did EPA, while purified 11-HEPE showed almost the
same inhibition level as EPA. In this study, 18-HEPE was
the most effective in suppressing the expression of
SREBP-1c and its target gene mRNAs. Especially, only 18-
HEPE significantly down-regulated GPA and PGC-1β
compared with T0901317-treated cells.
Of interest, 18-HEPE can be converted from EPA via
acetylated cyclooxygenase 2 (COX-2) in vascular endo-
thelial cells after treatment at local sites of inflammation
with aspirin, and is then rapidly converted by activated
5-lipoxygenase (5-LOX) in human polymorphonuclear
(PMN) leukocytes to insert molecular oxygen and in
subsequent steps through 5(6) epoxide formation to bio-
active Resolvin E1 (RvE1) and 15-epi-lipoxin (LX) A5,
the aspirin-triggered lipid mediators hydrolyzed from
5R, 6-epoxy-15R-HEPE [38,39]. These newly identified
chemical mediators appear to exert potent inflammatory
and pro-resolving actions both in vitro and in vivo as
proposed by many studies [40,41]. In addition, EPA can
be directly metabolized to 5-HEPE in human neutrophils
and eosinophils by activated 5-LOX, which has signifi-
cantly decreased biological effects compared to arachi-
donic acid-derived metabolites [42,43]. Kogure et al.
demonstrated that 5-HEPE is a potent agonist for GPR119
and enhances glucose-dependent insulin secretion [26].
Our study shows for the first time that the location of the
hydroxyl group on the carbon backbone of HEPEs is an
interesting factor that influences their performance in the
regulation of the lipogenesis pathway.
In summary, our data suggest that OEPA augments the
ameliorating effect of EPA on lipogenesis in liver cells via
the suppression of lipogenic genes related to SREBP-1c. In
addition, the preferable ameliorating effect of OEPA on
lipogenesis might be due to the decreases of the expres-
sions of PGC-1β and GPA by OEPA, meanwhile EPA does
not significantly differentiate those expressions. Our find-
ings provide insight into the importance of the location
and the number of hydroxy groups of OEPA in the
hypolipidemic effect. This study also suggests that oxida-
tion products as food components might contribute to the
beneficial effects of EPA on lipid metabolism in the liver
resulting in the prevention of CVD. However, further
in vivo experiments are necessary to ensure the effects of
dietary OEPA on lipid metabolism.
Materials and methods
Materials
Eicosapentaenoic acid and DL-α-tocopherol (vitamin
E) were purchased from Nacalai Tesque, Inc. (Kyoto,
Japan). T0901317, (±)-5-hydroxy-6E,8Z,11Z,14Z,17Z-
eicosapentaenoic acid ((±)5-HEPE), (±)-11-hydroxy-
5Z,8Z,12E,14Z,17Z-eicosapentaenoic acid ((±)11-HEPE),
and (±)-18-hydroxy-5Z,8Z,11Z,14Z,16E-eicosapentaenoic
acid ((±)18-HEPE) were obtained from Cayman Chemicals
(Ann Arbor, MI, USA).
Preparation of OEPA
EPA solution (equivalent of 10 mg) was added into
brown glass tubes and the diluted ethanol supernatant
was gently evaporated under a N2 stream. The prepared
tubes were incubated in a 40°C water bath for 4–24 h.
After incubation, OEPA was adjusted to a concentration
of 100 mM by diluting with ethanol. All samples were
stored at −80°C to preserve the quality of the OEPA
derivatives.
OEPA and HEPE analyses by liquid chromatography-mass
spectrometry (LC-MS)
For analyzing derivatives of EPA, OEPA and HEPEs, a
prominence HPLC system coupled to a LCMS-IT-TOF
spectrometer equipped with an electrospray ionization
interface (Shimadzu, Kyoto, Japan) was used. A TSK gel
ODS-100Z column (2.0 × 50 mm, 3 μm, Tosoh, Tokyo,
Japan) was eluted with methanol:water:acetate (70:30:0.01,
v/v) at a flow rate 0.2 ml/min. The MS was operated with
the following conditions: probe voltage of 1.50 kV, CDL
temperature of 200°C, block heater temperature of 200°C,
nebulizer gas flow of 1.5 L/min, ion accumulation time of
Nanthirudjanar et al. Lipids in Health and Disease 2013, 12:73 Page 8 of 11
http://www.lipidworld.com/content/12/1/73
50 msec, MS range of m/z 250 to 450, and CID parame-
ters were follows: energy, 50%; collision gas 50%.
Cell culture
HepG2 cells (JCRB 1054; Health Science Research Re-
sources Bank, Osaka, Japan) were cultured in DMEM
medium (Invitrogen, Carlsbad, CA, USA) containing
10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA)
and antibiotics (100 unit/ml penicillin and 100 μg/ml
streptomycin; Gibco Life Technologies Corp, Grand
Island, NY, USA) at 37°C in a humidified atmosphere in
the presence of 5% CO2.
Lipid extraction and quantification of TG
HepG2 cells were plated on 6-well plates at 5.0 × 105
cells/ml for 24 h in DMEM supplemented with 10%
fetal bovine serum and antibiotics as mentioned above.
The cells were then treated with EPA, OEPA and/or
T0901317 (10 nM) in the presence of vitamin E
(10 μM) in serum-supplemented medium. Fatty acids,
vitamin E and T0901317 were dissolved in ethanol (final
ethanol concentration of 0.3%). After incubation for
48 h, lipids were extracted from cells with chloroform-
methanol (2:1, v/v). Reference control cells were
extracted for cellular lipids before incubation (zero time
control). Collected supernatants were evaporated gently
under a N2 stream, and TG was quantified using a TG
E-test kit (Wako Pure Chemical Industries, Osaka,
Japan).
Determination of mRNA expression levels by real-time
RT-PCR
HepG2 cells were seeded in 12-well plates at 2.0 × 105
cells/ml in DMEM supplemented with 10% fetal bovine
serum and antibiotics. After 24 h of incubation, each
fatty acid was added to HepG2 cells with T0901317 (10
nM) in the presence of vitamin E (10 μM) in serum-free
medium containing 0.1% BSA (Sigma-Aldrich, Co., St.
Louis, MO, USA). The final ethanol concentration was
0.3%. After 24 h of incubation, total RNA was extracted
from the cells using Sepasol reagent (Nacalai Tesque,
Kyoto, Japan) according to the manufacturer’s instruc-
tions. RNAs were treated with RNase-free DNase
(Promega, Madison, WI, USA) to remove contaminating
genomic DNA. After inactivating DNase by adding
DNase stop solution (Promega, Madison, WI, USA) and
heating at 65°C for 10 min, each RNA was transcribed
to cDNA using SuperScript RNase II reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) with random hexamers
at 25°C for 10 min and then at 42°C for 50 min. The re-
actions were stopped by incubation at 70°C for 15 min.
To quantify the mRNA expression level, real-time quan-
titative RT-PCR was performed in a thermal cycler
(Bio-Rad Laboratories, Hercules, CA, USA) using iQ
SYBR Green supermix (Bio-Rad Laboratories, Hercules,
CA, USA). Primers used for the quantification of each
gene are listed in Table 1. Primer pairs were selected to
yield gene-specific single amplicons based on analyses
by melting curves and by agarose gel electrophoresis.
The thermal cycling conditions were as follows: 15 min
at 95°C for one cycle, followed by amplification of the
cDNA for 43 cycles with melting for 15 s at 95°C and
with annealing and extension for 30 s at 60°C. Values
were normalized against 18 s rRNA as an endogenous
internal standard.
Cell viability analysis
Cell viability was assessed by the WST-1 method. HepG2
cells were plated in 96-well culture plates at a density of
1.0 × 104 cells/well in 100 μl DMEM containing 10% fetal
bovine serum and antibiotics as detailed above, and were
incubated at 37°C for 24 h. Each fatty acid was then added
to HepG2 cells with T0901317 (10 nM) and/or vitamin E
(10 μM) in serum-free medium containing 0.1% BSA. The
final ethanol concentration was 0.3%. After incubation for
24 h at 37°C, 10 μl WST-1 solution (Dojindo Laboratories,
Co., Kumamoto, Japan) was added to each well to evaluate
cell viability. After incubation for 100 min at 37°C, cell via-
bility was measured using a microplate reader (Molecular
Devices Co., Sunnyvale, CA, USA) at a wavelength of
450 nm.
Table 1 Real-time RT-PCR primers used for the quantification of human mRNAs
Gene name Reference or Accession number Forward (from 5’ to 3’) Reverse (from 5’ to 3’)
SREBP-1c [45] GGAGGGGTAGGGCCAACGGCCT CATGTCTTCGAAAGTGCAATCC
SCD-1 NM_005063 TGGTTTCACTTGGAGCTGTG GGCCTTGGAGACTTTCTTCC
FAS [45] CAGGGACAACCTGGAGTTCT CTGTGGTCCCACTTGATGAGT
ACC1 NM_198834 ATCCCGTACCTTCTTCTACTG CCCAAACATAAGCCTTCACTG
ABCA1 [46] GCAAGGCTACCAGTTACATTTG GTCAGAAACATCACCTCCTG
GPA NM_020918 TTGGGTTTGCGGAATGTTAT GGCAGAACCATCAGGGTTTA
PGC-1β NM_133263 TGACTCCGAGCTCTTCCAG CGAAGCTGAGGTGCATGATA
18S [45] TAAGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC
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Cell fractionation and immunoblotting
HepG2 cells were plated in six-well plates at 5.0 × 105
cells/ml for 24 h in DMEM supplemented with 10% fetal
bovine serum and antibiotics as detailed above. The cells
were then treated with EPA, OEPA and/or T0901317
(10 nM) in the presence of vitamin E (10 μM) in serum-
free medium containing 0.1% BSA. After incubation for
24 h, membrane fractions and nuclear extracts from cells
were prepared by the method of Hannah et al. [44].
Briefly, cells were harvested by scraping and the cell sus-
pensions were centrifuged at 1,000 × g for 5 min at 4°C.
The cell pellets were resuspended in buffer A (250 mM
sucrose, 10 mM Hepes-KOH at pH 7.6, 10 mM KCl,
1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium
EGTA) containing protease inhibitors (Complete Mini
Protease Inhibitor tablet, Roche, Mannheim, Germany).
The cell suspensions were passed through a 23-gauge
needle 20 times and were centrifuged at 1,000 × g for
5 min at 4°C. The pellets were resuspended in 40 ul
Buffer B (20 mM Hepes-KOH at pH 7.6, 0.42 M NaCl,
2.5% (v/v) glycerol, 1.5 mM MgCl2, 1 mM sodium
EDTA, 1 mM sodium EGTA and protease inhibitors).
The suspensions were rotated at 4°C for 1 h and were
then centrifuged at 105 × g for 15 min at 4°C. The
resulting supernatant is designated as the nuclear extract
fraction. The supernatant of the original 1,000 × g spin
was centrifuged at 104 × g for 15 min at 4°C after which
the pellet was dissolved in 25 μl SDS lysis buffer
(10 mM Tris–HCl at pH 6.8, 100 mM NaCl, 1% (w/v)
SDS, 1 mM sodium EDTA, 1 mM sodium EGTA, and
protease inhibitors) and is designated as the membrane
fraction. The concentration of soluble proteins in the
supernatant was quantified using a DC protein assay kit
(Bio-Rad Laboratories, Hercules, CA, USA). For immu-
noblot analysis, given amounts of membrane fractions
(25 μg) and nuclear extracts (10 μg) were separated by
7% and 10% SDS-PAGE, respectively. Protein bands
were transferred to polyvinylidene difluoride membranes
(Millipore Corporation, Billerica, MA, USA). The filters
were probed with a rabbit polyclonal anti-SREBP-1 anti-
body (H-160, 1:400 dilution; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Bound antibodies were visualized
with alkaline phosphatase-conjugated anti-rabbit IgG
(1:500 dilution for membrane fractions and 1:1,000 for
nuclear extracts; Cell Signaling Technology, Danvers,
MA). The bands were visualized with the substrate,
chemi-lumione L (Nacalai Tesque, Kyoto, Japan) using a
FUJIFILM visualizer (LAS-3000, Fujifilm Corporation,
Tokyo, Japan).
Statistical analysis
Data are reported as means ± SD. Statistical analyses
were carried out by one-way ANOVA with Dunnett’s F-
test to identify significant difference using Stat View
software (SAS Institute, Cary, NC, USA).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TN, TH and TS designed the study. TN and HF performed the experiments.
TN and TS analyzed the data, wrote the first draft of manuscript and revised
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by the Kieikai Research Foundation.
Received: 5 April 2013 Accepted: 13 May 2013
Published: 16 May 2013
References
1. Ordovas JM: Genetic influences on blood lipids and cardiovascular
disease risk: tools for primary prevention. Am J Clin Nutr 2009,
89(suppl):1509S–1517S.
2. Serrano-Martinez M, Martinez-Losa E, Prado-Santamaria M, Brugarolas-Brufau
C, Fernandez-Jarne E, Martinez-Gonzalez MA: To what extent are the
effects of diet on coronary heart disease lipid-mediated? Int J Cardiol
2003, 95:35–38.
3. Rijzewijk LJ, Jonker JL, van der Meer RW, Lubberink M, De Jong HW, Romijn
JA, Bax JJ, De Roos A, Heine RJ, Twisk JW, Windhorst AD, Lammertsma AA,
Smit JW, Diamant M, Lamb HJ: Effects of hepatic triacylglyceride content
on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010,
56:225–233.
4. Vanni E, Bugianesi E, Kotronen A, Minicis SD, Yki-Jarvinen H, Svegliati-Baroni
G: From the metabolic syndrome to NAFLD or vice versa? Digest Liver Dis
2010, 42:320–330.
5. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van
Pelt RE, Wang H, Eckel RH: The metabolic syndrome. Endocr Rev 2008,
29:777–822.
6. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y,
Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T: Nonalcoholic
fatty liver disease is a novel predictor of cardiovascular disease. World J
Gastroenterol 2007, 13:1579–1584.
7. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C,
Arcado G: Prevalence of nonalcoholic fatty liver disease and its
association with cardiovascular disease among type 2 diabetic patients.
Diabetes Care 2007, 30:1212–1218.
8. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ,
Diamant M: Alanine aminotransferase predicts coronary heart disease
events: a 10-year follow-up of the hoorn study. Atherosclerosis 2007,
191:391–396.
9. Meisinger C, Doring A, Schneider A, Lowel H: Serum gamma-
glutamyltransferase is a predictor of incident coronary events in
apparently healthy men from the general population. Atherosclerosis
2006, 189:297–302.
10. Filion K, Khoury EI, Bielinski M, Schiller I, Dendukuri N, Brophy JM: Omega-3
fatty acids in high-risk cardiovascular patients: A meta-analysis of
randomized controlled trials. BMC Cardiovasc Disord 2010, 10:24.
11. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ,
Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA,
Ebrahim SB, Davey Smith G: Risks and benefits of omega 3 fats for
mortality, cardiovascular disease, and cancer: Systemic review. Brit Med J
2006, 332:752–760.
12. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A: Highly purified
eicosapentaenoic acid and docosahexaenoic acid in humans have
similar triacylglycerol-lowering effects but divergent effects on serum
fatty acid. Am J Clin Nutr 1997, 66:649–659.
13. Mori TA, Burke V, Puddey IB, Watts GF, O‘Neal DN, Best JD, Beilin LJ: Purified
eicosapentaenoic and docosahexaenoic acids have differential effects on
serum lipids and lipoproteins, LDL particle size, glucose, and insulin in
mildly hyperlipidemic men. Am J Clin Nutr 2000, 71:1085–1094.
14. Clarke SD: Nonalcoholic steatosis and steatohepatitis. I. Molecular
mechanism for polyunsaturated fatty acid regulation of gene
transcription. Am J Physiol Gastrointest Liver Physiol 2001, 281:G865–G869.
Nanthirudjanar et al. Lipids in Health and Disease 2013, 12:73 Page 10 of 11
http://www.lipidworld.com/content/12/1/73
15. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS: Differential
expression of exons 1a and 1c in mRNAs for sterol regulatory element
binding protein-1 in human and mouse organs and cultured cells.
J Clin Invest 1997, 99:838–845.
16. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, van der Sluijs
FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F: Stimulation of
lipogenesis by pharmacological activation of the liver X receptor leads
to production of large, triglyceride-rich very low density lipoprotein
particles. J Biol Chem 2002, 277:34182–34190.
17. Jiang XC, Beyer TP, Li Z, Liu J, Quan W, Schmidt RJ, Zhang Y, Bensch WR,
Eacho PL, Cao G: Enlargement of high density lipoprotein in mice via
liver X receptor activation requires apolipoprotein E and isabolished by
choleateryl ester transfer protein expression. J Biol Chem 2003,
278:49072–49078.
18. Ferre P, Foufelle F: SREBP-1c transcription factor and lipid homeostasis:
clinical perspective. Horm Res 2007, 68:72–82.
19. Kennedy EP: Biosynthesis of complex lipids. Fed Proc 1961, 20:934–940.
20. Lewin TM, Jong HD, Schwerbrock NJM, Hammond LE, Watkins SM, Combs
TP, Coleman RA: Mice deficient in mitochondrial glycerol-3-phosphate
acyltransferase-1 have diminished myocardial triacylglycerol
accumulation during lipogenic diet and altered phospholipid fatty acid
composition. Biochim Biophys Acta 2008, 1781:352–358.
21. Lin J, Tarr PT, Yang R, Rhee J, Puigserver P, Newgard CB, Spiegelman BM:
PGC-1β in the regulation of hepatic glucose and energy metabolism.
J Biol Chem 2003, 278:30843–30848.
22. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M,
Tontonoz P, Newgard CB, Spiegelman BM: Hyperlipidemic effects of
dietary saturated fats mediated through PGC-1β coactivation of SREBP.
Cell 2005, 120:261–273.
23. Majkova Z, Layne J, Sunkara M, Morris AJ, Toborek M, Hennig B: Omega-3
fatty acid oxidation products prevent vascular endothelial cell activation
by coplanar polychlorinated biphenyls. Toxicol Appl Pharm 2011,
251:41–49.
24. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN: Oxidized
omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions
through activation of PPARα. Blood 2002, 100:1340–1346.
25. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC,
Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams
GM, Reynet C: Deorphanization of a G protein-coupled receptor for
oleoylethanolamide and its use in the discovery of small-molecule
hypophagic agents. Cell Metab 2006, 3:167–175.
26. Kogure R, Toyama K, Hiyamuta S, Kojima I, Takeda S: 5-Hydroxy-
eicosapentaenoic acid is an endogenous GPR119 agonist and enhances
glucose-dependent insulin secretion. Biochem Biophys Res Commun 2011,
416:58–63.
27. Caputo M, Zirpoli H, Torino G, Tecce MF: Selective regulation of UGT1A1
and SREBP-1c mRNA expression by docosahexaenoic, eicosapentaenoic,
and arachidonic acids. J Cell Physiol 2010, 226:187–193.
28. Vanden Heuvel JP, Kreder D, Belda B, Hannon DB, Nugent CA, Burns KA,
Taylor MJ: Comprehensive analysis of gene expression in rat and human
hepatoma cells exposed to the peroxisome proliferator WY14,643.
Toxicol Appl Pharm 2003, 188:185–198.
29. Zaima N, Sugawara T, Goto D, Hirata T: Trans geometric isomers of EPA
decrease LXRα-induced cellular triacylglycerol via suppression of SREBP-
1c and PGC-1β. J Lipid Res 2006, 47:2712–2717.
30. Tanaka N, Zhang X, Sugiyama E, Kono H, Horiuchi A, Nakajima T, Kanbe H,
Tanaka E, Gonzalez FJ, Aoyama T: Eicosapentaenoic acid improves hepatic
steatosis independent of PPARα activation through inhibition of SREBP-1
maturation in mice. Biochem Pharmacol 2010, 80:1601–1612.
31. Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M, Matsuzaka T,
Nakakuki M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Takahashi A,
Sone H, Osuga JJ, Gotoda T, Ishibashi S, Yamada N: Polyunsaturated fatty
acids suppress sterol regulatory element-binding protein 1c promoter
activity by inhibition of liver X receptor (LXR) binding to LXR response
elements. J Biol Chem 2002, 277:1705–1711.
32. Gonzalaz-Baro MR, Lewin TM, Coleman RA: Regulation of triglyceride
metabolism. II. Function of mitochondrial GPAT1 in the regulation of
triacylglycerol biosynthesis and insulin action. Am J Physiol Gastrointest
Liver Physiol 2007, 292:1195–1199.
33. Dircks LK, Sul HS: Mammalian mitochondrial glycerol-3-phosphate
acyltransferase. Biochim Biophys Acta 1997, 1348:17–26.
34. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS:
Diminished hepatic response to fasting/refeeding and liver X receptor
agonists in mice with selective deficiency of sterol regulatory element-
binding protein-1c. J Biol Chem 2002, 227:9520–9528.
35. Okazaki H, Goldstein JL, Brown MS, Liang G: LXR-SREBP-1c-phospholipid
transfer protein axis controls very low density lipoprotein (VLDL) particle
size. J Biol Chem 2009, 285:6801–6810.
36. Ericsson J, Jackson SM, Kim JB, Spiegelman BM, Edwards PA: Identification
of glycerol-3-phosphate acyltransferase as an adipocyte determination
and differentiation factor 1- and sterol regulatory element-binding
protein-responsive gene. J Biol Chem 1997, 272:7298–7305.
37. Vega RB, Kelly DP: A role for estrogen-related receptor alpha in the
control of mitochondrial fatty acid beta-oxidation during brown
adipocyte differentiation. J Biol Chem 1997, 272:31693–31699.
38. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K: Novel
functional sets of lipid-derived mediators with inflammatory actions
generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal
antiinflammatory drugs and transcellular processing. J Exp Med 2000,
192:1197–1204.
39. Akarasereenont P, Techatrisak K, Chotewuttakorn S, Thaworn A: The
induction of cyclooxygenase-2 in IL-1 beta treated endothelial cells is
inhibited by prostaglandin E2 through cAMP. Mediators Inflamm 1999,
8:287–294.
40. Levy BD: Resolvin D1 and resolving E1 promote the resolution of allergic
airway inflammation via shared and distinct molecular counter-
regulatory pathways. Front Immuno 2012, 3:1–9.
41. Kang JX, Wang J, Wu L, Kang ZB: Transgenic mice: fat-1 mice convert n-6
to n-3 fatty acids. Nature 2004, 427:504.
42. Powell WS, Gravel S, Gravelle F: Formation of a 5-oxo metabolite of
5,8,11,14,17-eicosapentaenoic acid and its effects on human neutrophils
and ecosinophils. J Lipid Res 1995, 36:2590–2598.
43. Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF: Effects of
exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids
on the generation of 5-lipoxygenase pathway products by ionophore-
activated human neutrophils. J Clin Invest 1984, 74:1922–1933.
44. Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS: Unsaturated fatty
acids down-regulate SREBP isoforms 1a and 1c by two mechanisms in
HEK-293 cells. J Biol Chem 2001, 276:4365–4372.
45. Field FJ, Born E, Murthy S, Mathur SN: Poly-unsaturated fatty acids
decrease the expression of sterol regulatory element-binding protein-1
in CaCo-2 cells: effect on fatty acid synthesis and triacylglycerol
transport. Biochem. J 2002, 368:357–363.
46. Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR: Regulation of ABCA1
expression in human keratinocytes and murine epidermis. J Lipid Res
2006, 47: 2248–2258.
doi:10.1186/1476-511X-12-73
Cite this article as: Nanthirudjanar et al.: Oxidized eicosapentaenoic
acids more potently reduce LXRα-induced cellular triacylglycerol via
suppression of SREBP-1c, PGC-1β and GPA than its intact form. Lipids in
Health and Disease 2013 12:73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Nanthirudjanar et al. Lipids in Health and Disease 2013, 12:73 Page 11 of 11
http://www.lipidworld.com/content/12/1/73
